President Joe Biden has chosen Adm. Lisa Franchetti to lead the Navy, an unprecedented choice that, if she is confirmed, will make her the first woman to be a Pentagon service chief and the first female member of the Joint Chiefs of Staff.
A federal judge in West Virginia has ruled that the state corrections agency can’t force an incarcerated atheist and secular humanist to participate in religiously-affiliated programming to be eligible for parole.
The Senate Judiciary Committee is expected to vote Thursday on a new ethics code for the Supreme Court, an attempt to respond to recent revelations about justices’ interactions with wealthy donors and others. Republicans are strongly opposed, arguing the ethics bill could “destroy” the high court.
Protesters angered by the planned burning of a copy of the Quran stormed the Swedish Embassy in Baghdad early Thursday, breaking into the compound and lighting a small fire.
Exec tells first UN council meeting that big tech can’t be trusted to guarantee AI safety::An artificial intelligence company executive told the first U.N. Security Council meeting on AI’s threats to global peace that the handful of big tech companies leading the race to commercialize AI can’t be trusted to guarantee the...
An 18-year-old from suburban Denver who allegedly planned to go to Iraq to fight for the Islamic State group was arrested last week as he tried to board a flight to Turkey.
Prosecutors said companies that had won lucrative government contracts during Martinelli’s presidency funneled money to a front company that was then used to purchase the publisher. The transactions involved a complex series of foreign money transfers totally $43 million. The front company collecting the money was called...
A Florida judge who issued a court ruling last year that critics said was unduly favorable to Donald Trump is set to preside Tuesday over the first pretrial conference in his landmark criminal case concerning the mishandling of classified documents.
Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved Leqembi from Japanese drugmaker Eisai.